PD-L1 not only responds to the cGAS-STING pathway upon DNA damage, but also regulates cGAS-STING to induce inflammation. This ...
Immune checkpoint blockade is one of the major advances in cancer treatment in recent years. However, the majority of immune ...
An international team of UK and US scientists has discovered that the activity of macrophages—a type of white blood cell that ...
Tumors with a high level of TILs also have high expression of PD-L1, "but PD-L1-negative tumors ... nodes followed by the licensing of lymphatic cells that circulate back to the area of ...
Managed Healthcare Executive provides C-suite executives at health plans and provider organizations with news, analysis, ...
Immunotherapy has transformed cancer treatment, offering new avenues of hope for patients with advanced disease or limited ...
Imfinzi reduced risk of death by 27% and reduced disease progression by 24% compared to patients receiving a placebo. 2. In ...
Atezolizumab by F. Hoffmann-La Roche for Squamous Non-Small Cell Lung Cancer: Likelihood of Approval
Atezolizumab is under clinical development by F. Hoffmann-La Roche and currently in Phase III for Squamous Non-Small Cell Lung Cancer.
The FDA cleared the investigational new drug application for REC-4539, allowing for the start of a phase 1/2 trial in small ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback